Novel medical therapies for pituitary tumors
Despite considerable progress, there is still no medical treatment available for some kinds of pituitary tumors, in particular hormone inactive adenomas and corticotroph pituitary tumors. Surgical removal or at least debulking of the tumor is the only option to treat these kinds of tumors apart from...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2010
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 12419caa a22011897a 4500 | ||
|---|---|---|---|
| 001 | PAPER-7700 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230607131853.0 | ||
| 008 | 190411s2010 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-77955599941 | |
| 024 | 7 | |2 cas |a angiopeptin, 113294-82-9; bromocriptine, 25614-03-3; cabergoline, 81409-90-7; gamma interferon, 82115-62-6; octreotide, 83150-76-9; pasireotide, 396091-73-9; quinagolide, 97805-50-0; retinoic acid, 302-79-4; BIM 23A760; Dopamine Agonists; Interferon-gamma, 82115-62-6; Somatostatin, 51110-01-1; Tretinoin, 302-79-4; pasireotide | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 100 | 1 | |a Theodoropoulou, M. | |
| 245 | 1 | 0 | |a Novel medical therapies for pituitary tumors |
| 260 | |c 2010 | ||
| 270 | 1 | 0 | |m Theodoropoulou, M.; Max Planck Institute of Psychiatry, Department of Neuroendocrinology, Kraepelinstrasse 10, DE-80804 Munich, Germany |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Mancini, T., Casanueva, F.F., Giustina, A., Hyperprolac-tinemia and prolactinomas (2008) Endocrinol Metab Clin North Am, 37, pp. 67-99 | ||
| 504 | |a Renner, U., Arzberger, T., Pagotto, U., Leimgruber, S., Uhl, E., Müller, A., Lange, M., Stalla, G.K., Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically non-functioning pituitary adenomas (1998) J Clin Endocrinol Metab, 83, pp. 1368-1375 | ||
| 504 | |a Pivonelle, R., Matrone, C., Filippella, M., Cavallo, L.M., Di Somma, C., Cappabianca, P., Colao, A., Lombardi, G., Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with the effectiveness of caber-goline treatment (2004) J Clin Endocrinol Metab, 89, pp. 1674-1683 | ||
| 504 | |a Petrossians, P., Ronci, N., Valdes Socin, H., Kalife, A., Stevenaert, A., Bloch, B., Tabarin, A., Beckers, A., ACTH silent adenoma shrinking under cabergoline (2001) Eur J Endocrinol, 144, pp. 51-57 | ||
| 504 | |a Pivonello, R., Ferone, D., De Herder, W.W., Kros, J.M., Del Basso De Caro, M.L., Arvigo, M., Annunziato, L., Lamberts, S.W.J., Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors (2004) Journal of Clinical Endocrinology and Metabolism, 89 (5), pp. 2452-2462. , DOI 10.1210/jc.2003-030837 | ||
| 504 | |a De Bruin, C., Hanson, J.M., Meij, B.P., Kooistra, H.S., Waaijers, A.M., Uitterlinden, P., Swj, L., Hof-Land, L.J., Expression and functional analysis of dop-amine receptor subtype 2 and somatostatin receptor subtypes in canine cushinǵs disease (2008) Endocrinology, 149, pp. 4357-4366 | ||
| 504 | |a Greenman, Y., Tordjman, K., Osher, E., Veshchev, I., Shenkerman, G., Reider-Groswasser, I.I., Shegev, Y., Stern, N., Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth (2005) Clin Endocrinol, 63, pp. 39-44 | ||
| 504 | |a Lohmann, T., Trantakis, C., Biesold, M., Prothman, S., Guenzel, S., Schober, R., Paschke, R., Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline (2001) Pituitary, 4, pp. 173-178 | ||
| 504 | |a Weckbecker, G., Lewis, I., Albert, R., Schmid, H.A., Hoyer, D., Bruns, C., Opportunities in somatostatin research: Biological, chemical and therapeutic aspects (2003) Nat Rev Drug Discov, 2, pp. 999-1017 | ||
| 504 | |a Freda, P.U., Katznelson, L., Van Der Lely, A.J., Reyes, C.M., Zhao, S., Rabinowitz, D., Long-acting somatostatin analog therapy of acromegaly: A meta-analysis (2005) J Clin Endocrinol Metab, 90, pp. 4465-4473 | ||
| 504 | |a Patel, Y.C., Greenwood, M.T., Panetta, R., Demchyshyn, L., Niznik, H., Srikant, C.B., The somatostatin receptor family (1995) Life Sci, 57, pp. 1249-1265 | ||
| 504 | |a Lewis, I., Bauer, W., Albert, R., Chandramouli, N., Pless, J., Weckbecker, G., Bruns, C., A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential (2003) J Med Chem, 46, pp. 2334-2344 | ||
| 504 | |a Schmid, H.A., Pasireotide (SOM230): Development, mechanism of action and potential applications (2008) Mol Cell Endocrinol, 286, pp. 69-74 | ||
| 504 | |a Hofland, L.J., Van Der Hoek, J., Feelders, R., Van Aken, M.O., Van Koetsveld, P.M., Waaijers, M., Sprij-Mooij, D., Lamberts, S.W., The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5 (2005) Eur J Endocrinol., 152, pp. 645-654 | ||
| 504 | |a Batista, D.L., Zhang, X., Gejman, R., Ansell, P.J., Zhou, Y., Johnson, S.A., Swearingen, B., Klibanski, A., The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas (2006) J Clin Endocrinol Metab, 91, pp. 4482-4488 | ||
| 504 | |a Van Der Hoek, J., Waaijers, M., Van Koetsveld, P.M., Sprij-Mooij, D., Feelders, R.A., Schmid, H.A., Schoeffter, P., Hofland, L.J., Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells (2005) Am J Physiol Endocrinol Metab, 289, pp. E278-E287 | ||
| 504 | |a Boscaro, M., Ludlam, W.H., Atkinson, B., Glusman, J.E., Petersenn, S., Reincke, M., Snyder, P., Bertherat, J., Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): A multicenter, phase II trial (2009) J Clin Endocrinol Metab, 94, pp. 115-122 | ||
| 504 | |a Rocheville, M., Lange, D.C., Kumar, U., Patel, S.C., Patel, R.C., Patel, Y.C., Receptors for dopamine and soma-tostatin: Formation of hetero-oligomers with enhanced functional activity (2000) Science, 288, pp. 154-157 | ||
| 504 | |a Saveanu, A., Lavaque, E., Gunz, G., Barlier, A., Kim, S., Taylor, J.E., Culler, M.D., Jaquet, P., Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells (2002) J Clin Endocrinol Metab, 87, pp. 5545-5552 | ||
| 504 | |a Greenman, Y., Melmed, S., Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors (1994) J Clin Endocrinol Metab, 78, pp. 398-403 | ||
| 504 | |a Bevan, J.S., Webster, J., Burke, C.W., Scanlon, M.F., Dopamine agonists and pituitary tumor shrinkage (1992) Endocr Rev, 13, pp. 220-240 | ||
| 504 | |a De Bruin, T.W., Kwekkeboom, D.J., Van'T Verlaat, J.W., Reubi, J.C., Krenning, E.P., Lamberts, S.W., Croughs, R.J., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro (1992) J Clin Endocrinol Metab, 75, pp. 1310-1317 | ||
| 504 | |a Katznelson, L., Oppenheim, D.S., Coughlin, J.F., Kliman, B., Schoenfeld, D.A., Klibanski, A., Chronic somatosta-tin analog administration in patients with alpha-sub-unit-secreting pituitary tumors (1992) J Clin Endocrinol Metab, 75, pp. 1318-1325 | ||
| 504 | |a Florio, T., Barbieri, F., Spaziante, R., Zona, G., Hofland, L.J., Van Koetsveld, P.M., Feelders, R.A., Jaquet, P., Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: A multi-center study (2008) Endocr Relat Cancer, 15, pp. 583-596 | ||
| 504 | |a Newell-Price, J., Bertagna, X., Grossman, A.B., Nieman, L.K., Cushing's syndrome (2006) Lancet, 367, pp. 1605-1617 | ||
| 504 | |a Chambon, P., A decade of molecular biology of retin-oic acid receptors (1996) FASEB J, 10, pp. 940-954 | ||
| 504 | |a Zang, X.K., Hoffmann, B., Tran, P.B., Graupner, G., Pfahl, M., Retinoid X receptor is an auxiliary protein of thyroid hormone and retinoic acid receptors (1992) Nature, 355, pp. 441-446 | ||
| 504 | |a Páez-Pereda, M., Kovalovsky, D., Hopfner, U., Theo-Doropoulou, M., Pagotto, U., Uhl, E., Losa, M., Stalla, G.K., Retinoic acid prevents experimental Cushing syndrome (2001) J Clin Invest, 108, pp. 1123-1131 | ||
| 504 | |a Castillo, V., Giacomini, D., Páez-Pereda, M., Stalla, J., Labeur, M., Theodoropoulou, M., Holsboer, F., Arzt, E., Retinoic acid as a novel medical therapy for Cushing's disease in dogs (2006) Endocrinology, 147, pp. 4438-4444 | ||
| 504 | |a Labeur, M., Refojo, D., Wölfel, B., Stalla, J., Vargas, V., Theodoropoulou, M., Buchfelder, M., Stalla, G.K., Interferon-gamma inhibits cellular proliferation and ACTH production in corti-cotroph tumor cells through a novel Janus kinases-signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway (2008) J Endocrinol, 199, pp. 177-189 | ||
| 504 | |a Miller, M., Chen, S., Woodliff, J., Kansra, S., Curcumin (diferuloylmethane) nhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells (2008) Endocrinology, 149, pp. 4158-4167 | ||
| 504 | |a Vlotides, G., Siegel, E., Donangelo, I., Gutman, S., Ren, S.G., Melmed, S., Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands (2008) Cancer Res, 68, pp. 6377-6386 | ||
| 520 | 3 | |a Despite considerable progress, there is still no medical treatment available for some kinds of pituitary tumors, in particular hormone inactive adenomas and corticotroph pituitary tumors. Surgical removal or at least debulking of the tumor is the only option to treat these kinds of tumors apart from rarely applied radiotherapy. Moreover, treatment resistance is present in a considerable proportion of patients bearing pituitary tumors, for which medical treatment regimens are already available (prolactinomas, somatotroph adenomas). Thus, novel or improved medical treatment strategies would be desirable. Here, we summarize preclinical and clinical findings about the hormone and growth-suppressive action of various drugs, which will probably lead to novel future medical treatment concepts for pituitary tumors. Copyright © 2010 S. Karger AG, Basel. |l eng | |
| 593 | |a Max Planck Institute of Psychiatry, Department of Neuroendocrinology, Kraepelinstrasse 10, DE-80804 Munich, Germany | ||
| 593 | |a Affectis Pharmaceuticals, Munich, Germany | ||
| 593 | |a Departamento de Fisiología y Biología Molecular y Celular, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a ANGIOPEPTIN |
| 690 | 1 | 0 | |a BIM 23 A 387 |
| 690 | 1 | 0 | |a BIM 23 A 760 |
| 690 | 1 | 0 | |a BROMOCRIPTINE |
| 690 | 1 | 0 | |a CABERGOLINE |
| 690 | 1 | 0 | |a DOPAMINE RECEPTOR STIMULATING AGENT |
| 690 | 1 | 0 | |a GAMMA INTERFERON |
| 690 | 1 | 0 | |a OCTREOTIDE |
| 690 | 1 | 0 | |a PASIREOTIDE |
| 690 | 1 | 0 | |a QUINAGOLIDE |
| 690 | 1 | 0 | |a RETINOIC ACID |
| 690 | 1 | 0 | |a UNCLASSIFIED DRUG |
| 690 | 1 | 0 | |a ACROMEGALY |
| 690 | 1 | 0 | |a CANCER CHEMOTHERAPY |
| 690 | 1 | 0 | |a CANCER RADIOTHERAPY |
| 690 | 1 | 0 | |a CANCER SURGERY |
| 690 | 1 | 0 | |a CUSHING SYNDROME |
| 690 | 1 | 0 | |a GROWTH HORMONE SECRETING ADENOMA |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a HYPOPHYSIS TUMOR |
| 690 | 1 | 0 | |a MULTIMODALITY CANCER THERAPY |
| 690 | 1 | 0 | |a NEUROENDOCRINE TUMOR |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a PROLACTINOMA |
| 690 | 1 | 0 | |a REVIEW |
| 690 | 1 | 0 | |a DOPAMINE |
| 690 | 1 | 0 | |a DOPAMINE AGONISTS |
| 690 | 1 | 0 | |a HUMANS |
| 690 | 1 | 0 | |a INTERFERON-GAMMA |
| 690 | 1 | 0 | |a PITUITARY NEOPLASMS |
| 690 | 1 | 0 | |a SOMATOSTATIN |
| 690 | 1 | 0 | |a TRETINOIN |
| 653 | 0 | 0 | |a bim 23 a 387; bim 23 a 760; som 230 |
| 700 | 1 | |a Labeur, M. | |
| 700 | 1 | |a Paez Pereda, M. | |
| 700 | 1 | |a Haedo, M. | |
| 700 | 1 | |a Perone, M.J. | |
| 700 | 1 | |a Renner, U. | |
| 700 | 1 | |a Arzt, E. | |
| 700 | 1 | |a Stalla, G.K. | |
| 773 | 0 | |d 2010 |g v. 38 |h pp. 158-164 |p Front. Horm. Res. |x 03013073 |z 9783805594448 |t Frontiers of Hormone Research | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955599941&doi=10.1159%2f000318506&partnerID=40&md5=00cc9ebca4e70cdd41268346558babf4 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000318506 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_03013073_v38_n_p158_Theodoropoulou |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03013073_v38_n_p158_Theodoropoulou |y Registro en la Biblioteca Digital |
| 961 | |a paper_03013073_v38_n_p158_Theodoropoulou |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 68653 | ||